LHF-535

Category	Arenavirus
CAS	1450929-77-7
Description	LHF-535 is an antiviral agent that targets the arenavirus envelope glycoprotein, suggesting its potential use for the treatment of Lassa fever and other fevers caused by arenavirus.

Quotation Now

Synonyms	HY-112762; 2-[4-[(Z)-2-[1-(4-propan-2-yloxyphenyl)benzimidazol-5-yl]ethenyl]phenyl]propan-2-ol
Molecular Weight	412.52
Molecular Formula	C27H28N2O2
Canonical SMILES	CC(C)OC1=CC=C(C=C1)N2C=NC3=C2C=CC(=C3)C=CC4=CC=C(C=C4)C(C)(C)O
InChI	InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-
InChIKey	DBNZTRPIBJSUIX-WAYWQWQTSA-N
Purity	99.20%
Solubility	In vitro: 10 mM in DMSO
Appearance	Light yellow to yellow (Solid)
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	588
Exact Mass	412.215078140
In Vitro	LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC50 of 0.1-0.3 nM.
In Vivo	LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice.
Target	Arenavirus
XLogP3-AA	5.8